SEATTLE – June 12, 2018 – Seattle Children’s, with participating members Children’s National Health System, BC Children’s Hospital and Children’s Hospital Los Angeles, has launched CureWorks, an international collaborative of leading academic children’s hospitals determined to accelerate the development of immunotherapy treatments for childhood cancer. CureWorks focuses on expanding immunotherapy trials and patient access around the world, as well as sharing data and collective expertise to advance novel cell therapies.
CureWorks was founded on the idea that in order to revolutionize treatment for pediatric cancer, academic institutions must work together to achieve better treatments and outcomes for children. As the founding member, Seattle Children’s is seeing promising results in its chimeric antigen receptor (CAR) T-cell immunotherapy trials, and has one of the largest pipelines of open clinical trials aimed at treating pediatric blood and solid tumor cancers that do not respond to standard therapy by harnessing the immune system.
Seattle Children’s strongly believes there is an opportunity to combine the strengths of multiple hospital researchers into this collaborative effort to expand the reach of pediatric immunotherapy cancer trials. CureWorks will not only increase the number of immunotherapy trial sites around the globe, it will also aim to
Article originally posted at